Article
Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Aug 2024
Noma Isabella Harumi Yonehara, Carvalho Larissa Anastacio da Costa, Camarena Denisse Esther Mallaupoma, Silva Renaira Oliveira, Moraes Junior Manoel Oliveira de, de Souza Sophia Tavares, Newton-Bishop Julia, Nsengimana Jérémie, Maria-Engler Silvya Stuchi
Abstract excerpt
The second most common mutation in melanoma occurs in NRAS oncogene, being a more aggressive disease that has no effective approved treatment. Besides, cellular plasticity limits better outcomes of the advanced and therapy-resistant patients. Peroxiredoxins (PRDXs) control cellular processes through direct hydrogen peroxide oxidation or by redox-relaying processes. Here, we demonstrated that PRDX2 could act as a...
Topics
- Humans
- Melanoma
- Peroxiredoxins
- Cell Line, Tumor
- GTP Phosphohydrolases
- Mutation
- Neoplasm Invasiveness
- Membrane Proteins
- Epithelial-Mesenchymal Transition